Navigation Links
Invida Selects LaVoie Group as Public Relations Agency of Record
Date:2/8/2010

;" target="_blank" title="our clients">our clients include emerging and leading global brands in the life science sector, such as Pfizer, sanofi-aventis, Vertex Pharmaceuticals, Genetix Pharmaceuticals, Rockwell Medical, Cardioxyl Pharmaceuticals, and Profectus Biosciences.

In 2009, LaVoie Group was selected for three industry awards including the coveted Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP) and the Bell Ringer merit award for corporate identity by the New England Publicity Club. LaVoie Group is also ranked by O’Dwyer’s PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit http://www.lavoiegroup.com.

Contact:
Donna L. LaVoie
President & CEO
LaVoie Group
978-745-4200 X103
http://www.lavoiegroup.com

# # #

Read the full story at http://www.prweb.com/releases/Invida_Group/LaVoie_Group/prweb3573384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data
2. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
3. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
4. Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development
5. Leading Global CRO Selects iCardiac as Preferred Vendor
6. The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
9. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
10. iSirona Selects New Chairman of the Board
11. Memorial Sloan-Kettering Selects Artemis as Affiliate for India
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Invida Selects LaVoie Group as Public Relations Agency of Record
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Trial Programs Funded Through 2009, SAN FRANCISCO, ... Ottawa, Ontario), a clinical stage biopharmaceutical company,developing a ... announced the closing of a financing transaction with,gross ... of $8 million USD.,The offering was completed without ...
... or dusts be protected by UL certified lights that have an ... of these lights available for oil rig workers and paint spray ... ... 2008 -- OSHA requirements mandate that workers exposed to flammable vapors ...
... FRANCISCO, Sept. 9 VIA Pharmaceuticals,Inc. (Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... on Tuesday, September 16, 2008 at 12:00pm,Eastern Time ... Libby, Chief of,Cardiovascular Medicine at the Brigham and ...
Cached Biology Technology:Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 2Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 3Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 3VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 4
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... WASHINGTON, Pa., Nov. 30, 2011 ADFLOW Health ... digital messaging focused on Consumer Health Engagement and ... screening kiosks—Personal Health Centers™—in all Rite Aid locations. ... The agreement with ADFLOW demonstrates Rite ...
... WASHINGTON, Nov. 30Ultra-tiny zinc oxide (ZnO) particles with ... the ingredients list of some commercially available sunscreen products, ... beneath the outer layer of skin. To help ... from Australia and Switzerland have developed a way to ...
... a pair of physicians at Boston University School of Medicine ... development of a test that can help diagnose membranous nephropathy ... offered in the research setting and is awaiting commercial development, ... the disease. Currently, the only way to diagnose the disease ...
Cached Biology News:ADFLOW Health Networks to Provide Blood Pressure Screening Centers at Rite Aid Pharmacies Nationwide 2Scientists use laser imaging to assess safety of zinc oxide nanoparticles in sunscreen 2BUSM researchers develop blood test to detect membranous nephropathy 2
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: